Literature DB >> 32903928

Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review.

Toshihiko Masago1,2, Susumu Kobayakawa3, Yuu Ohtani4, Kenjirou Taniguchi4, Takuji Naka4, Naoto Kuroda5, Chihiro Takahashi1, Tadahiro Isoyama1, Takehiro Sejima2.   

Abstract

A 68-year-old man was followed up with chronic kidney disease. Follow-up CT incidentally detected a tumor at the left kidney and multiple small nodular shadows in the lungs bilaterally. The patient underwent needle biopsy and was diagnosed with Xp11.2 translocation renal cell carcinoma (RCC) pathologically. Hence, laparoscopic nephrectomy was performed. Fluorescence in situ hybridization analysis revealed a break-apart of the transcription factor E3 (TFE3) genes in the left tumor. After 2 months postoperatively, nivolumab and ipilimumab were administered thrice intravenously, considering the intermediate risk by the IMDC risk classification. However, pleural effusion occurred but was removed adequately. Lung metastasis decreased, but new metastasis occurred at the left iliopsoas muscle. Target therapy was performed with axitinib. Unfortunately, he died 6 months later postoperatively. These tumors commonly occur in children than in adults, and very rare in elderly patients. Xp11.2 translocation RCC in the elderly has a poorer prognosis than that in children. To date, no effective treatment for Xp11.2 translocation RCC has been established. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Fluorescence in situ hybridization; Xp11.2 translocational renal cell carcinoma

Year:  2020        PMID: 32903928      PMCID: PMC7450002          DOI: 10.1007/s13691-020-00430-6

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  15 in total

1.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

Authors:  John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  JAMA Oncology Patient Page. Immune Checkpoint Inhibitors.

Authors:  Howard Jack West
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

3.  The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene.

Authors:  S K Sidhar; J Clark; S Gill; R Hamoudi; A J Crew; R Gwilliam; M Ross; W M Linehan; S Birdsall; J Shipley; C S Cooper
Journal:  Hum Mol Genet       Date:  1996-09       Impact factor: 6.150

4.  Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.

Authors:  Guido Martignoni; Stefano Gobbo; Philippe Camparo; Matteo Brunelli; Enrico Munari; Diego Segala; Maurizio Pea; Franco Bonetti; Peter B Illei; Georges J Netto; Marc Ladanyi; Marco Chilosi; Pedram Argani
Journal:  Mod Pathol       Date:  2011-05-20       Impact factor: 7.842

5.  Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma.

Authors:  J Clark; Y J Lu; S K Sidhar; C Parker; S Gill; D Smedley; R Hamoudi; W M Linehan; J Shipley; C S Cooper
Journal:  Oncogene       Date:  1997-10       Impact factor: 9.867

Review 6.  A case of renal cancer with TFE3 gene fusion in an elderly man. Clinical, radiological and surgical findings.

Authors:  Aldo Franzini; Stefano Carlo Maria Picozzi; Paolo Luca Politi; Luigi Barana; Fabio Bianchi; Giuseppe Alfano; Giampiera Gatti; Franco Fanciullacci; Massimo Gariboldi; Mirella Strada; Biagio Eugenio Leone
Journal:  Urol Int       Date:  2007       Impact factor: 2.089

7.  Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report.

Authors:  Xiang Pan; Jing Quan; Liwen Zhao; Wenhua Li; Benlin Wei; Shangqi Yang; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2017-11-13

8.  Morphologic and molecular characterization of renal cell carcinoma in children and young adults.

Authors:  Elisabeth Bruder; Oliver Passera; Dieter Harms; Ivo Leuschner; Marc Ladanyi; Pedram Argani; John N Eble; Kirsten Struckmann; Peter Schraml; Holger Moch
Journal:  Am J Surg Pathol       Date:  2004-09       Impact factor: 6.394

9.  PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration.

Authors:  Mukul Mathur; Sharmistha Das; Herbert H Samuels
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

10.  Bilateral Xp11.2 translocation renal cell carcinoma: a case report.

Authors:  Takashi Karashima; Takahira Kuno; Naoto Kuroda; Hirofumi Satake; Satoshi Fukata; Masakazu Chikazawa; Chiaki Kawada; Ichiro Yamasaki; Taro Shuin; Makoto Hiroi; Keiji Inoue
Journal:  BMC Urol       Date:  2018-11-20       Impact factor: 2.264

View more
  6 in total

1.  A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment.

Authors:  Takashi Yoshida; Toshiaki Tanaka; Tetsuya Shindo; Yuki Kyoda; Kohei Hashimoto; Ko Kobayashi; Tadashi Hasegawa; Naoya Masumori
Journal:  Int Cancer Conf J       Date:  2022-02-21

2.  The Latinx Disparity in Surgery for Kidney Cancer: Data from The South Texas Region.

Authors:  Furkan Dursun; Rahul S Patel; Dawn Hui; Hanzhang Wang; Ahmed Mansour; Deepak Pruthi; David G Alonso; Lalithapriya Jayakumar; Ronald Rodriguez; Robert S Svatek; Michael A Liss; Dharam Kaushik
Journal:  Kidney Cancer J       Date:  2022-03-17

3.  Masseter Muscle Metastasis of Renal Cell Carcinoma: A Case Report and Literature Review.

Authors:  Fei Qin; Xiaofei Zhang; Jie Zhang; Shuaihong Liu; Zijie Wang; Fei Xie; Mingxin Zhang; Tianwei Zhang; Shuangyi Wang; Wei Jiao
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

4.  Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report.

Authors:  Juping Zhao; Kun Dai; Jialing Xie; Chen Fang; Na Chen; Jun Dai; Danfeng Xu
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

Review 5.  Autophagy in Xp11 translocation renal cell carcinoma: from bench to bedside.

Authors:  Huimin Sun; Xing Wei; Changchun Zeng
Journal:  Mol Cell Biochem       Date:  2021-08-03       Impact factor: 3.396

6.  Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.

Authors:  Yuqing Wu; Saisai Chen; Minhao Zhang; Kuangzheng Liu; Jibo Jing; Kehao Pan; Lihua Zhang; Bin Xu; Xiaoming Lu; Ming Chen
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.